肿瘤免疫治疗技术与产品开发的现状与发展建议

doi:10.13523/j.cb.20170115

中国生物工程杂志

2017, Vol. 37

Issue (1): 104-110 DOI: 10.13523/j.cb.20170115

行业分析

肿瘤免疫治疗技术与产品开发的现状与发展建议

卢姗, 李苏宁, 范红

中国生物技术发展中心北京 100039

Progress and Prospect on Technology and Products Development of Tumor Immunotherapy

LU Shan, LI Su-ning, FAN Hong

China National Center for Biotechnology Development, Beijing 100039, China

全文: PDF(507 KB) HTML

摘要：

近年来，肿瘤免疫治疗研究取得了突破性进展，相关技术与产品研发呈爆发式增长，众多生物技术公司和制药公司纷纷投入其中，国际竞争日趋激烈。未来我国如何能够抓住机遇，在国际竞争中脱颖而出是当前亟待思考的问题。通过对肿瘤疫苗，以CAR-T和TCR-T为代表的过继细胞疗法和以PD-1/PD-L1靶点为核心的免疫检查点抗体及药物研究的主要产品、技术和研究方向的全面梳理，加深对本领域发展现状的整体把握。通过分析上述代表性肿瘤免疫疗法的技术特点和发展趋势，为研发工作提供参考，同时针对我国在该领域的研发现状与存在的问题，提出加强统筹规划、注重基础研究、重视专利保护以及加强科学监管的发展建议，为如何更好的发展我国肿瘤免疫治疗领域提供参考意见。

关键词： 免疫治疗; 政策建议; 产品开发; 肿瘤

Abstract:

In recent years, the breaking-through progress has been made in the research of tumor immunotherapy, and the explosive growth has been obtained in the R&D of related technology and product. Great investment has been made by many Biotech Corp and pharmaceutical companies, the international competition is becoming increasingly fierce. The emerging question confronting China is how to seize the opportunities and stand out in the international competition. An overall understanding of the development situation of the field through a comprehensive analysis of the main products, technology and future research direction of the dendritic cell-based vaccine and adoptive cell transfer therapy (ACT) featured are gtiven by CAR-T and TCR-T and anti-tumor immune checkpoint inhibitors targeted to PD-1/PD-L1, and reference for R&D work through the analysis of the technical features and development trend of immunotherapy represented by the above mentioned three approaches are provided. And for the R&D situation and the existing problems in this field, suggestions such as strengthening the overall planning, focusing on basic research, emphasizing the patent protection, enhancing the scientific supervision, are put forward to provide a reference on how to make a better development of China's tumor immune therapy.

Key words: Tumor Products development Policy suggestion Immunotherapy

收稿日期: 2016-07-19 出版日期: 2017-01-25

ZTFLH:

Q352

通讯作者: 卢姗 E-mail: lushan@cncbd.org.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

卢姗, 李苏宁, 范红. 肿瘤免疫治疗技术与产品开发的现状与发展建议[J]. 中国生物工程杂志, 2017, 37(1): 104-110.

LU Shan, LI Su-ning, FAN Hong. Progress and Prospect on Technology and Products Development of Tumor Immunotherapy. China Biotechnology, 2017, 37(1): 104-110.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20170115 或 https://manu60.magtech.com.cn/biotech/CN/Y2017/V37/I1/104

[1] Rosenberg S A, Lotze M T, Muul L M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine, 1987, 316(15):889-897.
[2] Mellman I, Coukos G, Dranoff G.Cancer immunotherapy comes of age.Nature,2011,480(22/29):480-489.
[3] Topalian S L, Weiner G J, Pardoll D M.Cancer immunotherapy comes of age. Journal of Clinical Oncology,2011,29(36):4828-4836.
[4] DeVita V T, Jr Rosenberg S A. Rosenberg.Two hundred years of cancer research. The New England Journal of Medicine,2012,366(23):2207.
[5] 钱其军.肿瘤免疫治疗何去何从:多角度的换位思考.中国肿瘤生物治疗杂志, 2016,23(3):308-313. Qian Q J.Where do we go now for cancer immunotherapy:transpositional consideration from different angles. Chinese Journal of Cancer Biotherapy,2016,23(3):308-313.
[6] Rosenberg S A, Restifo N P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, 348(6230):62-68.
[7] Witte M D, Coccoris M, Wolkers M C. Targeting self antigens through allogeneic TCR gene transfer. Molecular Therapy, 2004, 9(3):S103.
[8] Kayser S, Bob C, Feucht J, et al. Rapid generation of NY-ESO-1-specific CD4⁺ THELPER1 cells for adoptive T-cell therapy. Oncolmmunology, 2015, 4(5):e1002723.
[9] Porter D L, Hwang W T, Frey N V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7(303):303ra139.
[10] Barrett D M, Grupp S A, June C H. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. The Journal of Immunology, 2015, 195(3):755-761.
[11] Sharma P 1, Allison J P. The future of immune checkpoint therapy. Science, 2015, 348(6230):56-61.
[12] Weintraub K. The cancer defense. Scientific American, 2016, 314(4):42-51.
[13] Holko P,Kawalec P. Economic evaluation of sipuleucel-T immunetherapy in castration-resistant prostate cancer. Expert Review of Anticancer Therapy,2014,14(1):63-73.
[14] 万涛, 陈国友, 范颂华, 等. 大肠癌树突状细胞治疗性疫苗的Ⅰ/Ⅱ期临床研究//中国免疫学会,中国免疫学会第五届全国代表大会暨学术会议论文摘要, 中国免疫学会第五届会员代表大会,镇江,2006, 镇江:中国免疫学会,2006:390. Wan T, Chen G Y, Fan S H, et al. Phase I/II Clinical Trial on Therapeutic Vaccine for Colorectal Carcinoma Dendritic Cells//In:Chinese Society for Immunology, Paper Abstracts of the 5^th National Academic Conference of Chinese Society for Immunology, the 5^th National Academic Conference of Chinese Society for Immunology, Zhenjiang, 2006, Zhenjiang:Chinese Society for Immunology, 2006:390.
[15] 姚冰清,张俊萍.基于树突状细胞的抗肿瘤策略与思考.中国癌症防治杂志.2016,8(1):55-58. Yao B Q, Zhang J P. Thinking of dendritic cell-based anticancer strategy. Chinese Journal of Oncology Prevention and Treatment, 2016, 8(1):55-58.
[16] Yao B Q,Zhang J P.Thinking of dendritic cell-based anticancer strategy.Chinese Journal of Oncology Prevention and Treatment,2016,8(1):55-58.
[17] Yang W, Bai Y B, Xiong Y. Potentiating the antitumour response of CD8⁺ T cells by modulating cholesterol metabolism. Nature, 2016, 531(7596):651-655.

[1]	赵梦泽,李凤智,王鹏银,李剑,徐寒梅. PD-L1和VEGF双靶点联合阻断治疗的研究进展[J]. 中国生物工程杂志, 2021, 41(9): 71-77.
[2]	吕慧中,赵晨辰,朱链,许娜. 外泌体靶向递药在肿瘤治疗中的进展[J]. 中国生物工程杂志, 2021, 41(5): 79-86.
[3]	原博,王杰文,康广博,黄鹤. 双特异性纳米抗体的研究进展及其应用 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 78-88.
[4]	邓蕊,曾佳利,卢雪梅. 基于Musca domestica cecropin的抗肿瘤小分子衍生肽筛选及构效关系解析^*[J]. 中国生物工程杂志, 2021, 41(11): 14-22.
[5]	尹政清,白京羽,林晓锋. 美国生物医药产业竞争力分析与启示[J]. 中国生物工程杂志, 2020, 40(9): 87-94.
[6]	蔺士新,刘东晨,雷云,熊盛,谢秋玲. TNF-α纳米抗体的筛选、表达及特异性检测 ^*[J]. 中国生物工程杂志, 2020, 40(7): 15-21.
[7]	杨威,宋方祥,王帅,张黎,王红霞,李焱. 药物输送系统中Janus纳米粒子的制备及应用 ^*[J]. 中国生物工程杂志, 2020, 40(7): 70-81.
[8]	张保惠,熊华龙,张天英,袁权. 基于水疱性口炎病毒(VSV)的溶瘤病毒研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(6): 53-62.
[9]	童梅,程永庆,刘金毅,徐晨. 促进大肠杆菌周质空间小分子抗体表达的菌种构建方法^*[J]. 中国生物工程杂志, 2020, 40(5): 48-56.
[10]	戴奇男,张景红. 肿瘤多药耐药与自噬、DNA修复和肿瘤干细胞相关的分子机制研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(4): 69-77.
[11]	钱颖,钱晨,白晓庆,王晶晶. 免疫佐剂在肿瘤免疫疗法中的应用进展 ^*[J]. 中国生物工程杂志, 2020, 40(3): 96-103.
[12]	肖雪筠,唐奇,新华·那比. 靶向肿瘤微环境的CAR-T治疗研究^*[J]. 中国生物工程杂志, 2020, 40(12): 67-74.
[13]	何询,张鹏,张俊祥. 类器官的构建与应用进展[J]. 中国生物工程杂志, 2020, 40(12): 82-87.
[14]	朱永朝,陶金,任萌萌,熊燃,何亚琴,周瑜,卢震辉,杜勇,杨芝红. 自噬抑制肿瘤坏死因子α诱导人胎盘胎儿来源间充质干细胞发生凋亡 ^*[J]. 中国生物工程杂志, 2019, 39(9): 62-67.
[15]	彭贤贵,杨武晨,李佳,苟阳,王平,刘思恒,张云,李艺,张曦. 细胞形态相关技术在血液系统肿瘤中的应用 ^*[J]. 中国生物工程杂志, 2019, 39(9): 84-90.

Viewed

Full text

Abstract

Cited

Shared

Discussed